Cancer Family
Secondary Neoplasm
CI-CAN-00000050Explore in graph →
Non-malignant4,271 active trials56 approved drugs532 evidence items
- NCIt
- C36255
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000050Explore in graph →
Clinical trials
14,666 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00423306 | A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma | completed | Phase 2 | 15 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors |
| completed |
| Phase 2 |
| 144 |
| ECOG-ACRIN Cancer Research GroupNETWORK |
| 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT02613819 | Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney(FASTRACK II) | completed | Phase 2 | 71 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT02743741 | Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors | completed | N/A | 195 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05057247 | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | completed | Phase 2 | 26 | Kartik Sehgal, MDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05176223 | 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer | completed | Phase 2 | 26 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05273554 | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03030404 | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | completed | — | 733 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05007106 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT05540925 | Vascular Invasion Prediction Via a Multimodal Model Supports Re-staging of Early-stage Hepatocellular Carcinoma | completed | — | 3,650 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05880160 | Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction(HER-SAFE) | completed | N/A | 90 | University College, LondonOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07144384 | Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma | completed | Early Phase 1 | 4 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07845266 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 13 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03643510 | Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer | completed | Phase 2 | 27 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04626479 | Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) | completed | Phase 1 / Phase 2 | 393 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT04626518 | Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) | completed | Phase 1 / Phase 2 | 263 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT07024680 | Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC(PRCC) | completed | — | 48 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07842055 | AI-based Prognostic Factors Identification in Early-stage Invasive Lobular Breast Carcinoma | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04145141 | National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer | completed | — | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04489771 | A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013) | completed | Phase 2 | 154 | Merck Sharp & Dohme LLCINDUSTRY | 9 | Sep 24, 2026 | clinicaltrials |
| NCT05188118 | Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | completed | Early Phase 1 | 10 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06799286 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer | completed | Phase 1 | 10 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07820228 | Survival Analysis of Early Triple Negative Breast Cancer (TNBC) Women Treated With Dose Dense Sequential Adjuvant Chemotherapy | completed | — | 3,648 | Hellenic Cooperative Oncology GroupOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03387553 | HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer | completed | Early Phase 1 | 31 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03967951 | CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms | completed | — | 70 | Francesco De CobelliOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT00001452 | Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex | completed | — | 1,387 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04522570 | Thermal Ablation of Cervical Metastases From Thyroid Carcinoma | completed | N/A | 84 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03455270 | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | completed | Phase 1 | 107 | G1 Therapeutics, Inc.INDUSTRY | 7 | Sep 21, 2026 | clinicaltrials |
| NCT04512209 | Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology(DCE-MRI) | completed | N/A | 22 | University Hospital, GhentOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT05153239 | Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) | completed | Phase 3 | 705 | PharmaMarINDUSTRY | 24 | Sep 21, 2026 | clinicaltrials |
| NCT06014086 | Intratumoral PH-762 for Cutaneous Carcinoma | completed | Phase 1 | 22 | Phio Pharmaceuticals Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07829900 | First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer | completed | — | 2,250 | Xin LiOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831083 | Skin Cancer Among Outdoor Workers(Skin Cancer Am) | completed | — | 10,000 | Assuta Medical CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04053842 | Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy(IGPC-5) | completed | Phase 2 | 16 | Glenn BaumanOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665856 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02C) | completed | Phase 3 | 123 | Hoffmann-La RocheINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827482 | Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma | completed | — | 228 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03460080 | Diagnostic Value of AFP-L3 and PIVKA-II in HCC | completed | — | 200 | Hanoi Medical UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05249426 | A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer | completed | Phase 1 | 48 | Boehringer IngelheimINDUSTRY | 11 | Sep 16, 2026 | clinicaltrials |
| NCT02598219 | Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.(SENTIRAD) | completed | Phase 3 | 262 | Centre Oscar LambretOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06236425 | TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC | completed | Phase 1 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT01300143 | Association of Conformational High-dose Radiotherapy and of Hyperselective Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma(TACERTE) | completed | Phase 2 | 126 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04191460 | Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer(GuidedbyLight) | completed | Phase 2 | 31 | Erasmus Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01807065 | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | completed | Phase 2 | 51 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06033092 | Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion(TOLERANT) | completed | Phase 2 | 110 | European Institute of OncologyOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 16 hours agoSource updated Sep 29, 2026source: clinicaltrials